Proof of concept that beneficial strains could be deliberately seeded
From the earliest moments of life, a mother's body offers her newborn more than nourishment — it offers a microbial inheritance. Irish researchers, working across four institutions, have now mapped with unprecedented precision how beneficial gut bacteria pass from mother to infant, finding that the circumstances of birth and the presence of antibiotics shape this transfer in ways that carry lifelong health consequences. Published in Nature Communications, the MicrobeMom study opens a quiet but significant door: the possibility of designing probiotic supplements that could be given during pregnancy to deliberately seed an infant's gut before they take their first breath.
- The transfer of Bifidobacterium from mother to newborn — long assumed but poorly understood — has now been charted in granular detail, revealing a process far more fragile and contingent than previously known.
- Delivery method emerged as a decisive variable: spontaneous vaginal births produced the greatest microbial diversity and highest transfer rates, while other methods left infants with measurably thinner bacterial inheritance.
- Antibiotic exposure during labour significantly reduced the number of beneficial bacterial strains reaching the infant, raising urgent questions about clinical trade-offs made routinely in delivery rooms.
- Though the specific Bifidobacterium strain tracked transferred with low efficiency, researchers reframed this as opportunity — proof that targeted strains could be deliberately administered to mothers to seed infant guts.
- The study's layered methodology — combining metagenomic sequencing, culture techniques, and whole genome sequencing — gives its findings unusual credibility and positions the team to design the next generation of prenatal probiotic interventions.
A team spanning APC Microbiome Ireland, PrecisionBiotics Group, University College Dublin's Perinatal Research Centre, and the National Institute for Bioprocessing, Research and Training has completed what they call the most thorough examination yet of how beneficial gut bacteria travel from mother to newborn. The project, known as MicrobeMom, centred on Bifidobacterium — bacteria that colonise the infant gut early and carry measurable benefits including reduced risk of allergies and asthma, stronger immune function, and improved digestion.
What the researchers found was both clarifying and sobering. The transfer does happen, but it is shaped by circumstances largely outside anyone's control. Delivery method proved critical: spontaneous vaginal births produced significantly greater microbial diversity and higher transfer rates than other methods. Antibiotic exposure during labour, meanwhile, substantially reduced the number of strains making the journey from mother to child.
The particular Bifidobacterium strain the team tracked did not transfer with high efficiency — but principal investigator Prof Paul Cotter described this not as failure but as proof of concept. A low natural transfer rate, he argued, actually demonstrates that specific strains could be deliberately administered to mothers, seeding their infants' guts with beneficial microbes in a targeted way. Prof Fionnuala McAuliffe of UCD called the mapping work 'significant and exciting,' noting the layered methodology — metagenomic sequencing, culture techniques, and whole genome sequencing — gave the team an unusually detailed view of the process.
Published in Nature Communications, the study points toward a concrete next step: developing probiotic supplements timed to pregnancy and delivery that could enhance natural bacterial transfer, potentially improving immune development and reducing allergic disease in ways that follow children well into their lives.
A team of Irish researchers has completed what they describe as the most thorough examination yet of how beneficial gut bacteria pass from mother to newborn, a discovery that could reshape how we think about early infant health and the design of probiotic treatments.
The work, called MicrobeMom, emerged from a collaboration between APC Microbiome Ireland (a Science Foundation Ireland research centre), PrecisionBiotics Group, University College Dublin's Perinatal Research Centre, and the National Institute for Bioprocessing, Research and Training. The team focused on a particular type of bacteria called Bifidobacterium, which plays a significant role in health from infancy through adulthood. What they found was both straightforward and nuanced: mothers do transfer these bacteria to their infants, but the process is shaped by forces largely beyond anyone's control—how the baby is born, whether antibiotics are used during labour, and other clinical circumstances.
The research revealed that Bifidobacterium colonizes infant guts early and brings measurable benefits. The bacteria help reduce the likelihood of allergies and asthma developing, strengthen immune function, increase resistance to microbial infection, and support digestive health. These findings suggest a clear pathway: if scientists can understand and optimize the transfer of these beneficial strains, they might be able to design probiotic supplements that mothers could take during pregnancy, allowing the bacteria to reach their infants before birth or during delivery.
But the study also uncovered something important about the mechanics of transfer. Delivery method emerged as a critical factor. Vaginal births, particularly those that occur spontaneously without intervention, showed significantly greater microbial diversity and higher transfer rates than other delivery methods. Antibiotic exposure during labour, by contrast, substantially reduced the number of bacterial strains that made the journey from mother to child. The particular Bifidobacterium strain the researchers tracked did not transfer with high efficiency, but Prof Paul Cotter, the principal investigator at APC, framed this as valuable proof of concept rather than failure. The low transfer rate, he explained, actually demonstrates that targeted bacterial strains could be deliberately administered to mothers as a way to seed their infants' guts with beneficial microbes.
Prof Fionnuala McAuliffe, a professor of obstetrics and gynaecology at UCD and director of the Perinatal Research Centre, called the mapping work "significant and exciting." The team used a combination of metagenomic sequencing, culture techniques, and whole genome sequencing—a layered approach that allowed them to see the bacterial transfer with unprecedented detail. They identified specific clinical factors that support beneficial transfer, with spontaneous vaginal birth standing out as particularly favourable.
The study was published in Nature Communications, lending it considerable weight in the scientific community. What emerges from the work is a clearer picture of a biological process that has always occurred but was never fully understood. The implications are substantial: if researchers can develop probiotic interventions timed to pregnancy and delivery, they might be able to enhance the natural transfer process, potentially improving immune development, reducing allergic disease, and supporting digestive health in ways that could benefit children throughout their lives. The next phase will involve exploring whether deliberately administered bacterial supplements during pregnancy can improve strain transfer to infants—a question that could reshape prenatal care.
Notable Quotes
The low transfer rate demonstrates that targeted bacterial strains could be deliberately administered to mothers as a way to seed their infants' guts with beneficial microbes.— Prof Paul Cotter, APC Microbiome Ireland
This in-depth investigation has identified key clinical factors associated with beneficial bacterial transfer, such as spontaneous vaginal birth.— Prof Fionnuala McAuliffe, UCD Perinatal Research Centre
The Hearth Conversation Another angle on the story
Why does it matter that we understand how these bacteria move from mother to baby? Isn't that just how biology works?
It matters because we've never actually mapped it in detail before. Once you see the mechanism clearly—that delivery method and antibiotics change the outcome—you can start to intervene. Right now it's mostly chance. With this knowledge, you could design a probiotic that actually reaches the infant's gut.
So the bacteria don't always transfer efficiently?
No. The particular strain they tracked in this study transferred at low rates. But that's actually the point—it proves you could give mothers a supplement and have it reach the baby. It's proof of concept.
What about the antibiotics finding? That seems like it could be a real problem for some mothers.
It is. Antibiotics during labour reduce bacterial transfer significantly. So you have this tension: antibiotics are sometimes medically necessary, but they also disrupt this natural seeding process. Understanding that trade-off is important for clinical decision-making.
And vaginal birth versus other delivery methods—is that saying one is better?
The data shows vaginal birth, especially spontaneous labour, has higher bacterial transfer and more microbial diversity. But the researchers aren't making a moral argument. They're identifying a biological fact that could inform how we design interventions or counsel parents.
What's the actual health benefit to the infant?
Bifidobacterium helps prevent allergies and asthma, strengthens immunity, and supports digestion. These aren't small things. If you could optimize that transfer through a probiotic, you're potentially improving health outcomes across childhood.